Anteris Technologies Global Corp. — AGM Information 2007

Nov 12, 2007

CHAIRMAN’S ADDRESS

FOURTH Annual General Meeting of bioMD Ltd

13 November 2007 – Chifley on the Terrace Hotel, 185 St Georges Terrace, Perth

OVERVIEW:

bioMD is in the commercialisation stage of the ADAPT Tissue Processing Technology, through our subsidiary– Celxcel Pty Ltd. We now hold a 76.3% interest in Celxcel.

During the past year, we have

• completed further ADAPT pre-clinical animal trials;

• Been granted ethics approval to commence a Phase II Human clinical trial in South Africa of cardiovascular heart patches. We anticipate this trial will commence in the first quarter of 2008;

• Progressed our joint venture with CSIRO to the final decision gate; and

• Commenced marketing of the pre-filled syringe finalised prototype from our original suite of injection therapy products.

Turning to the financial results for the year ended 30 June 2007:

RESULTS:

The operating result of the Company for the year ended 30 June 2007 amounted to a loss of $2.2 million (2006: $1.2 million). This included a $1.3 million impairment loss, that wrote off the value of our intellectual property and patents related to the ADAPT process.

The entry was recorded only because we do not have confirmed sales contracts over our technology. However, we will be able to reverse these impairment charges in the future,

upon signing agreements with third parties that will support the carrying value of our intangible assets.

We currently have 84.3 million shares on issue. During October, we issued a Prospectus currently open, which is due to close on 30 November. The offer is for new shares at a price of 20 cents each. As an incentive, the applicant will receive four attached new options for no additional consideration. Each new option is to be exercisable at 25 cents for one fully paid ordinary share in the company on or before 5pm WST on 30 August 2010. We intend to apply to the ASX to list these options.

bioMD continues to maintain its Quality Assurance certification with the appropriate standards for regulatory product approvals both within Australia and overseas.

OUTLOOK:

The outlook for the next financial year is an exciting one, with the move into the human clinical trial and completion of our QA and TGA registration for a biological tissue patch for use in the cardiovascular area.